Organogenesis Holdings (ORGO) Depreciation & Amortization (CF) (2018 - 2026)
Organogenesis Holdings (ORGO) posted quarterly Depreciation & Amortization (CF) of $4.2 million for Q1 2026, up 21.2% year-over-year from $3.4 million in Q1 2025, and up 2.66% quarter-over-quarter from $4.1 million in Q4 2025.
Organogenesis Holdings (ORGO) Depreciation & Amortization (CF) (2018 - 2026) Analysis & Trends
Organogenesis Holdings' Depreciation & Amortization (CF) history runs 9 years deep, the most recent figure standing at $4.2 million for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 21.2% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $16.0 million (up 14.35% YoY), while the FY2025 annual figure was $15.3 million, up 12.11% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $4.2 million, up from $4.1 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $4.2 million in Q1 2026, with the low at $1.3 million in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $3.1 million (2024), against an average of $2.9 million.
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) retreated 24.83% in 2022, then jumped 100.0% in 2023.
- Organogenesis Holdings' Depreciation & Amortization (CF) stood at $1.5 million in 2022, then soared by 96.96% to $3.0 million in 2023, then increased by 21.23% to $3.6 million in 2024, then rose by 12.48% to $4.1 million in 2025, then rose by 2.66% to $4.2 million in 2026.
- Business Quant data shows ORGO's Depreciation & Amortization (CF) at $4.2 million in Q1 2026, $4.1 million in Q4 2025, and $4.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Organogenesis Holdings | 241.91 Mn | 195.06 Mn | 20.08 Mn | 3.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.67 Mn |
| Jun 30, 2026 | 3.67 Mn |
| Mar 31, 2026 | 4.17 Mn |
| Mar 31, 2026 | 4.17 Mn |
| Dec 31, 2025 | 4.07 Mn |
| Dec 31, 2025 | 4.07 Mn |
| Sep 30, 2025 | 4.03 Mn |
| Sep 30, 2025 | 4.03 Mn |
| Jun 30, 2025 | 3.73 Mn |
| Jun 30, 2025 | 3.73 Mn |
| Mar 31, 2025 | 3.44 Mn |
| Mar 31, 2025 | 3.44 Mn |
| Dec 31, 2024 | 3.62 Mn |
| Dec 31, 2024 | 3.62 Mn |
| Sep 30, 2024 | 3.57 Mn |
| Sep 30, 2024 | 3.57 Mn |
| Jun 30, 2024 | 3.37 Mn |
| Jun 30, 2024 | 3.37 Mn |
| Mar 31, 2024 | 3.07 Mn |
| Mar 31, 2024 | 3.07 Mn |